ProQR Doses First Patient in AX-0811 Phase 1 Trial for Cholestatic…

Event summary

ProQR dosed the first participant in the Phase 1 trial of AX-0811, a next-generation RNA editing oligonucleotide for cholestatic liver diseases.
AX-0811 targets NTCP modulation and shows greater potency and longer half-life than its predecessor AX-0810 in preclinical studies.
Initial Phase 1 target engagement data for the first two cohorts is expected in early January 2027.
ProQR will host a virtual investor and analyst educational event on September 30, 2026, featuring presentations by management and Gideon Hirschfield.

The big picture

ProQR's dosing of the first participant in the AX-0811 Phase 1 trial marks a critical step in its efforts to develop disease-modifying treatments for cholestatic liver diseases. The company's Axiomer RNA editing technology platform positions it at the forefront of a growing field focused on precision RNA therapies. Success in this trial could validate ProQR's approach and attract further investment, while failure could raise questions about the platform's broader applicability.

What we're watching

Clinical Efficacy: Whether AX-0811's preclinical advantages in potency and half-life translate into meaningful clinical benefits for patients with cholestatic liver diseases.
Regulatory Pathway: The pace at which ProQR can advance AX-0811 through clinical trials and secure regulatory approvals for biliary atresia and other cholestatic conditions.
Competitive Positioning: How ProQR's Axiomer platform differentiates it from competitors in the RNA editing space, particularly in targeting liver diseases.